Loading stock data…
IXHL
$3.67+0.27 (+7.94%)
After Hours$3.64-0.03 (-0.82%)· Last close Jun 9
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Incannex Healthcare Inc. in the Healthcare sector is trading at $3.67. The stock is currently near its 52-week low of $2.49, remaining 59.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.67
Potential Downside
0%
Whystock Fair Value$3.67
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose com...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.34%
Volume
Today's trading volume
449,084
Recent News
Incannex Healthcare Inc. (IXHL) Implements 1-for-30 Reverse Split Effective February 26
Incannex Healthcare Inc. (NASDAQ:IXHL) is among the 11 Best Pot Stocks to Buy According to Hedge Funds. On February 25, Incannex Healthcare Inc. (NASDAQ:IXHL) announced that its board of directors approved a 1-for-30 reverse stock split of the company’s common stock. The reverse split had previously been approved by stockholders at a special meeting held […]
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Tilray Rebranded Italian Medical Cannabis Arm as Tilray Medical Italia Aurora Cannabis Won EU-wide Protection for its Farm Gas and Sourdough Cannabis Varieties Simply Solventless Sharpened Growth Strategy with Uncommon Cannabis Acquisition and Humble Retrofit Progress Key Takeaways; Psychedelic Sector Definium Therapeutics Launched ‘Rerouting Minds’ Campaign to Spotlight the Science Behind […]
What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock
Incannex Healthcare Inc. (IXHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1% and the Hea
Wall Street Set to Open Higher Friday as Investors Await Powell's Speech at Jackson Hole
US stocks are set to open higher in Friday's trading session as investors look ahead to Federal Rese